Disease Information

General Information of the Disease (ID: DIS00563)

• Name: Mature T-cell lymphoma
• ICD: ICD-11: 2A90

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 7 drug(s) in total

Cyclophosphamide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Resistant Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Resistant Drug: Cyclophosphamide
• Molecule Alteration: Expressiom; L747S
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Etoposide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Sensitive Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Sensitive Drug: Etoposide
• Molecule Alteration: Expressiom; Down-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Hydrocortisone

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Sensitive Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Sensitive Drug: Hydrocortisone
• Molecule Alteration: Expressiom; Down-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Methotrexate

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Sensitive Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Sensitive Drug: Methotrexate
• Molecule Alteration: Expressiom; Down-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Tofacitinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Resistant Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Resistant Drug: Tofacitinib
• Molecule Alteration: Expressiom; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Venetoclax

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Resistant Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Resistant Drug: Venetoclax
• Molecule Alteration: Expressiom; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Vincristine

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Resistant Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Resistant Drug: Vincristine
• Molecule Alteration: Expressiom; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: CAMPATH-1 antigen (CD52) [1]

• Sensitive Disease: t-cell prolymphocytic leukemia [ICD-11: 2A90.0]
• Sensitive Drug: Vincristine
• Molecule Alteration: Expressiom; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: T-cell prolymphocytic leukemia patient; Homo sapiens
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: Overall survival assay
• Mechanism Description: MTX-HOPE is a combination of classical chemotherapy agents originally developed for palliative chemotherapy in frail patients with refractory lymphoma. MTX-HOPE has been reported to be effective against T-cell tumors. Severe nonhematologic adverse events are rarely reported; however, bone marrow suppression is commonly observed.

References

• Ref 1: Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab. JMA J. 2024 Oct 15;7(4):642-645.